Egyptian International Pharmaceutical Investments (CAI:PHAR) Long-Term Debt : E£2,832 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Long-Term Debt?

Egyptian International Pharmaceutical Investments's Long-Term Debt for the quarter that ended in Dec. 2023 was E£2,832 Mil.

Egyptian International Pharmaceutical Investments's quarterly Long-Term Debt increased from Jun. 2023 (E£0 Mil) to Sep. 2023 (E£2,586 Mil) and increased from Sep. 2023 (E£2,586 Mil) to Dec. 2023 (E£2,832 Mil).

Egyptian International Pharmaceutical Investments's annual Long-Term Debt increased from Dec. 2021 (E£529 Mil) to Dec. 2022 (E£812 Mil) and increased from Dec. 2022 (E£812 Mil) to Dec. 2023 (E£2,832 Mil).

Egyptian International Pharmaceutical Investments Long-Term Debt Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Long-Term Debt Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

529.07

812.13

2,832.32

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Long-Term Debt	Get a 7-Day Free Trial															812.13	1,326.23	-	2,586.17	2,832.32

Egyptian International Pharmaceutical Investments (CAI:PHAR) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Egyptian International Pharmaceutical Investments Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Egyptian International Pharmaceutical Investments's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.